The Danish EpiTherapeutics ApS is developing new cancer drugs with primarily focus on prostate cancer. In the future, the medication may also be used for other clinical areas. This week, it has been announced that SEED Capital sells the company to Gilead Sciences for € 57 millions.
“BRIC and the University of Copenhagen deserve a great tribute for their research and work towards commercialization. We are very pleased that EpiTherapeutics now have new owners who can help lift the technology to new heights” says Carsten Schou, General Partner in SEED Capital.
The American Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Previously, the company has two major hepatitis C drugs.
For SEED Capital, this transaction is the 5th exit during the last year. The total value of exited companies this year is now stunningly € 400 million.
